Groove Botanicals Inc. (GRVE) Cash & Equivalents (2010 - 2026)

Groove Botanicals has reported Cash & Equivalents for 12 years, with the latest figure at $1502.0 in Q1 2026.

• Quarterly Cash & Equivalents fell 26.44% year-over-year to $1502.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1502.0 (down 26.44% YoY) and the FY2026 annual result came in at $1502.0, down 26.44% from the prior year.
• Cash & Equivalents grew to $1502.0 in Q1 2026 per GRVE's latest filing, from $1494.0 in the prior quarter.
• Over five years, Cash & Equivalents peaked at $6133.0 in Q3 2024 and troughed at $1251.0 in Q4 2024.
• A 4-year average of $2544.9 and a median of $2096.0 in 2023 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2024 and 2025: Cash & Equivalents soared 115.5% in 2024, then tumbled 75.67% in 2025.
• Over 4 years, Cash & Equivalents stood at $2150.0 in 2023, then slumped by 41.81% to $1251.0 in 2024, then gained by 19.42% to $1494.0 in 2025, then grew by 0.54% to $1502.0 in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $1502.0, $1494.0, and $1492.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.